Investor Presentation

May 2025

REPLIGEN

Safe Harbor / Non-GAAP financial measures

This presentation contains forward-looking statements within the meaning of the federal securities laws. Statements in this presentation which are not strictly historical statements including, without limitation, express or implied statements or guidance regarding Repligen's financial results for full year 2025, future financial performance and other statements identified by words like "estimated," "anticipated," "guidance," or "goal," and similar expressions are forward-looking statements. These statements are subject to risks and uncertainties which may cause our plans to change or actual results to differ materially from those anticipated. In particular, unforeseen events outside of our control may adversely impact future results. Additional information concerning these factors is discussed in our reports filed with the Securities and Exchange Commission including recent Form 8-Ks, our most recent Annual Report on Form 10-K and our most recent Quarterly Reports on Form 10-Q, all of which are available on our website. The forward-looking statements in this presentation reflect management's current views and may become obsolete as a result of new information, future events or otherwise. We may not update such forward looking statements to reflect a change of events or circumstances that occur after the date hereof, except as required by law. The industry and market data contained in this presentation are based on management's own estimates, independent publications, government publications, reports by market research firms or other published independent sources, and, in each case, are believed by management to be reasonable estimates. Although we believe these sources are reliable, we have not independently verified the information. This presentation discloses certain financial measures not prepared in accordance with generally accepted accounting principles, or GAAP. Repligen strongly encourages investors to review our consolidated financial statements and publicly filed reports in their entirety and cautions investors that the non-GAAP measures used herein may differ from similar measures used by other companies, even when similar terms are used to identify such measures.

Who is Repligen?

REPLIGEN

Repligen Snapshot: The Innovation Leader in Bioprocessing

- Supporting Biopharma and CDMOs with a broad and differentiated portfolio of hardware & consumables used in biological drug production
- Innovation engine … disrupting norms with bioprocessing technologies that deliver on yield gains, cost efficiencies and speed-to-market
- Global manufacturing presence with security of supply
- ~65% clinical, 35% commercial
- Revenue driven by proteins e.g. mAbs (~80%) with strong and growing presence in new modalities (~18%)

>1,700 employees worldwide

Performing Above Market

- Since 2014, **14** disruptive product launches, **15** acquisitions
- **19%** 5-year revenue growth (CAGR)



We are 10 years "young" … and Fit for Growth!

Strong End Markets with Positive Trends Entering 2025

mAb-based Therapeutics
Most mature, largest, steady

8-10% Projected CAGR
194 US FDA approvals
~2K Ph 1-3 clinical pipeline

Biosimilar mAbs
Rapidly expanding subset



>20% Projected CAGR
49 US FDA approvals
>150 Ph 1-3 clinical pipeline

New Modalities
Youngest, fastest growing

>30% Projected CAGR
31 US FDA approvals
>3K in development pipeline

Market Trends

- Biopharma market growing HSD with aging population
- Development and manufacturing costs under more scrutiny
- Local governments pushing for localization
- U.S. biggest region for sales, APAC for trials
- Generative AI already playing a key role in drug discovery and beyond

REPLIGEN

US FDA approval data as of May 9, 2025 *Projected CAGR is for 4-year period from proprietary research reports*

Broad Portfolio Across the Bioproduction Workflow; Addressing Pain Points



Shaded parts of the workflow identifies steps Repligen does not currently address (bioreactors, cell culture media and virus inactivation)

How Are We Different?

Our approach to winning through differentiation

REPLIGEN

Repligen's Value Creation Equation

Strategy

- ✓ 100% Bioprocessing including Analytics
- ✓ Disruptive technology launches to generate productivity gains
- ✓ Extensive portfolio across mAbs and new modalities workflows
- ✓ Disciplined M&A with strong return creates differentiation

+

Capabilities

- ✓ Innovation enabling customer efficiency
- ✓ Our culture … nimble, collaborative, transparent
- ✓ Commercial & Operations excellence
- ✓ Fit for Growth … talent, expertise, process rigor

=

Results: 2014 to 2024

- ✓ 10-fold increase in revenue
- ✓ Adj. EPS $0.24 to $1.58
- ✓ 3-fold increase in TAM

Confident in our ability to grow above market and expand margin over the next 5 years

Executing our Algorithm for Consistent Growth Above Market

Ways we grow above market	Delivered through product launches & differentiated M&A
1. **Create solutions** for unmet needs that expand the overall market	✓ Process intensification; single use XCell® ATF ✓ OPUS® Pre-Packed Columns (Scalable from PD to LS)
2. **Increase our position** in existing market segments	✓ Filtration/Fluid Management portfolio expansion ✓ Filtration and Chrom Systems, integrated with single-use consumables and in-line Analytics
3. **Benefit from our mix** of faster growth segments	✓ New modalities +3x since 2019; ~18% of 2024 revenue ✓ Weighted to clinical programs, benefiting from scale-up

Repeatable approach to expand our Total Addressable Market (TAM) and grow above market

Expanding our Total Addressable Market: $12B of ~$20B Total



We increased our TAM by 3x over four years through:

- ✓ Strategic M&A, R&D, entry into new markets
- ✓ Creation of new markets
- ✓ Expanded portfolio, workflow coverage and functionality of our products, e.g. integrated systems
- ✓ Example: Filtration TAM up 400% due to:
  - Addition of Fluid Management (portfolio expansion)
  - Purpose-built solutions for new modalities
  - Growth in existing markets with gold standard products

At ~5% market share, we have ample room for growth

Differentiated M&A: High Potential Technology, Strategic Relevance

Filtration

Refine
TangenX
Spectrum
Artesyn
Polymem
/
Bioflex
EMT, NMS
FlexBiosys
Metenova

Chrom

Atoll GmbH

Proteins

Avitide
Tantti

Analytics



C Technologies
908 Devices' Bioprocessing

Cross-franchise compatibility, connectivity, integration

15
2014-2025

Disciplined M&A

What we look for:

- **Technology first**
  - Differentiated, flexible, scalable
  - Complementary or synergistic
- **Strategic relevance**
  - Adds to or leverages capabilities
  - Expands our presence across workflow
- **Aligns with strict financial criteria**

Deals to date

- 4 transformative, 11 tuck-ins
- 7 all cash, 8 cash & equity

2025 focus

- Remain active, selective
- Not a requisite to drive DD growth

REPLIGEN

Technology Leadership

REPLIGEN

Flagship Products: Gold Standard Technology, Integrated Systems

XCell® ATF Systems

Filtration
Fluid Mgmt.

First and only Alternating Tangential Flow (ATF) device;
The go-to for upstream process intensification

"1/4 the CapEx, 1/3 the OpEx, 1/10 the Footprint in 1/2 the Time"
(Large pharma customer)

- Reduces bioreactor size, increased throughput, yield and capacity
- 10x viable cell density
- 20-fold increased yield
- Ready to Scale (from pilot- to commercial)

Growth propelled by wins in late-stage clinical and commercial processes

KRM Chromatography Systems with OPUS® pre-packed columns

State-of-the-art integrated chroma system

- Effortless scale up where "every drop counts"
- 100% single-use and simple
- No dead-legs, minimal hold-up volume, greater product recovery
- Reduced human error, contamination risk, down time



Proteins
Chroma
Fluid Mgmt

The Next 5-10 Years

Positioning for continued success

REPLIGEN

Evolution of Our Bioprocessing Business



- Diversified customer base; largest customer represented ~6% of FY-24 revenues
- Continued launch of differentiated products and M&A enables a broadening portfolio offering
- Product portfolio is well diversified and end-market agnostic
- New modalities continues to be a strategic end-market and growth driver long-term
- Revenue shift from clinical to commercial exposure over time as we scale with our customers

Diversified portfolio, customer base, and end-markets through M&A and organic investments

Well-Positioned for The Digitization Journey



The Digitization Model continues to mature

- **Process Modeling & Automation** broadly utilized to speed R&D and improve manufacturing productivity
- **PAT** technologies have been introduced “at-line” and “in-line” and starting to be used more broadly in manufacturing to monitor process
- **Data** needs to be stored in secured Cloud environment offered by digital providers
- **Data Analysis** via AI is becoming the next big thing to generate significant productivity gains

Repligen Acquires 908 Devices' Bioprocessing Product Portfolio (March 2025)

- ✓ **Important strategic acquisition** in our journey to enable digitization in bioprocessing
- ✓ Acquiring **differentiated products for key PAT technologies** (Raman spectroscopy, Mass Spectrometry, Biosensing, Electrophoresis) … **Complements our existing downstream PAT**
- ✓ First step in our strategy to bring **PAT-integrated upstream solutions** to the bioprocessing industry, as we have done in downstream … a multi-year journey
- ✓ **Talent injection** of top tier analytics scientists and engineers
- ✓ **Contributes ~$10M** to 2025 revenue … **accretive to gross margin**
- ✓ **Leveraging our commercial organization** and upstream presence with ATF
- ✓ **$70M cash purchase: ~6X 2024 revenue multiple,** fully funded from strong cash position

Continuing our execution of strategic acquisitions with disciplined evaluation

PAT Portfolio Overview: Driving Process Efficiency & Productivity

REBEL

2019 LAUNCH

Microfluidics CZE + MS

- At-line cell culture media monitoring and analysis
- Simplifies media selection, QC, optimization
- 50% titer improvement; 2,000x faster than Mass Spec and HPLC
- Results on 30+ nutrients and metabolites in under 10 mins

Improved Cell Culture Performance

REBEL Video

MAVERICK



2023 2H LAUNCH

Raman powered, purpose-built "de novo" model

- Bioprocess analysis and control with no prior modeling
- In-line, real-time monitoring and control of multiple CPPs
- Faster deployment, lower setup and operating cost
- Control of up to 6 bioreactors

Faster Process Optimization

MAVERICK Video

MAVEN

2023 1H LAUNCH

Diffusion Probe & Biosensing

- Real-time monitoring and control of CPPs (glucose and lactate) in cell culture and fermentation
- Aseptic monitoring with no loss of bioreactor volume
- 8x reduction in glycation in production runs

Higher Product Quality & Yield

MAVEN Video

ZipChip

2016 LAUNCH

Microfluidics CZE

- High resolution sample separation for characterization of CQAs
- Charge variant analysis, peptide mapping, metabolite quant.
- 20x faster, more precise than Liquid Chromatography MS

Increased Precision and Sensitivity

REPLIGEN

CZE: Capillary zone electrophoresis, MS: Mass Spectrometry CPPs: Critical Product Parameters CQAs: Critical Quality Attributes

Fit for Growth … the People, Culture and Processes to Grow

People & Culture

- Retain & attract great talent … developing leaders for the future
- Collaborate across functions … fast decision making

Ops Excellence

- Optimized global footprint … concentrate investments on state-of-the-art ‘anchor’ sites, while maintaining security of supply
- Win with world-class quality and differentiated services

Business Processes

- RPS as a process to drive continuous improvement & a simplification mindset
- Harmonize systems and processes … less complex, more transparent & efficient

Disciplined structure … Prioritization … Selective investments

Wrap Up

Financial Highlights & 2025 Priorities

REPLIGEN

Financial Highlights

Revenue Growth



Adj. EPS - Diluted



Cash Flow from Ops



Balance Sheet

$697M

Cash balance 3/31/25

End of 2028

Debt Maturity

Top Financial Value Creation Levers

1. Compelling above-market revenue growth trajectory
2. Commitment to margin expansion and continued cost discipline … productivity execution and leverage as revenue returns to historical growth
3. Generating solid operating cash flows … minimal capex required for capacity over next several years
4. Capital structure provides flexibility with low-cost debt, available dry powder

Q1 2025 Business Highlights

<u>Q1-25 Financial Highlights:</u>

- Revenue: +10% reported
  - +11% organic
  - +14% organic, non-COVID
- Orders
  - Increased sequentially and nearly 20% year-over-year
  - All four franchises grew double-digits year-over-year
  - New modalities >20% year-over-year
  - >50% opportunity funnel >30%
- Margins
  - Adj. GM: 53.7% (+440 bps year-over-year)
  - Adj. OM: 13.8% (+490 bps year-over-year)
  - Cash balance: $697M at 3/31/25

<u>Business Highlights:</u>

- Pharma and consumables revenues at record levels non-COVID
- Closed on acquisition of 908 Devices' bioprocessing portfolio
- Launched CTech™ SoloVPE® Plus System

REPLIGEN

2025 Financial Guidance

Financial Guidance Adjusted (non-GAAP)	Current April 29, 2025	Prior February 20, 2025
Revenue	**$695M to $720M**	**$685M - $710M**
Reported Growth	9.5% - 13.5%	8% - 12%
Organic Growth	9.5% - 13.5%	9.5% - 13.5%
Organic, Non-COVID Growth	11.5% - 15.5%	11.5% - 15.5%
Non-COVID Growth	11.5% - 15.5%	10% - 14%
Gross Margin	**52% - 53%**	**51% - 52%**
Operating Margin	**13.5% - 14.5%**	**14% - 15%**
Adj. EBITDA Margin	**19.5% - 20.5%**	**20% - 21%**
Net Income	**$92M - $97M**	**$95M - $100M**
EPS (Fully-Diluted)	**$1.63 - $1.72**	**$1.67 - $1.76**

Current guidance incorporates the impact of the acquisition of 908 Devices' Bioprocessing Analytics business including: a revenue increase of $10 million, a $4 million reduction in income from operations and the associated impact on operating margin, adjusted EBITDA margin, net income and earnings per share, diluted. Additionally, there was a 100-basis point increase in gross margin versus our prior guidance. This primarily related to a shift in costs to operating expenses from cost of goods sold, where they previously were assumed in our prior guidance. There is no impact on operating income associated with this change.

Our 2025 Priorities

Top 5 Priorities	Framework
1. Accelerate growth with a transformed customer experience	Low-double digit growth ex-COVID; increased investment in APAC
2. Expand margins	100 – 200 bps EBIT expansion (ex-M&A)
3. Continue to innovate (R&D)	Disruptive new product launches
4. Pursue and integrate M&A	1 – 2 deals
5. Fit For Growth	Process and investment discipline

Wrap up … Why Repligen?

- ✓ Breakthrough innovation is in our DNA … positively influencing the future of bioprocessing
- ✓ Top industry expertise and proven track record; capability to scale
- ✓ Earned reputation for customer centricity, flexibility and quick execution
- ✓ Well defined algorithm to continue to grow above market

Thank You!

REPLIGEN

Appendix

Repligen Tariff and Foreign Exchange Exposure

Tariff Exposure Type	Exposure	Mitigation
Manufactured OUS Sold in US	• ~90% manufactured in the US or exempt from tariffs	• Surcharges
Manufactured in US, Sold OUS (ex-China)	• ~25% of consolidated revenue. Believe majority exempt from tariffs	• Surcharges • Leveraging global footprint
China	• ~2% of 1Q25 revenue • ~35% of China revenue manufactured OUS • <1% of FY25 revenue subject to China tariffs	• Moved some finished goods into the region ahead of tariffs • Leveraging global footprint • Have added key leaders for APAC and China as we view this region as an important long-term growth opportunity
Raw Materials	• ~10% of COGS from raw materials directly sourced outside of the manufacturing region	• Pricing, where appropriate
Foreign Exchange Rates	• Assumed a 1.5% headwind in FY25 guide. At current Fx rates, this could represent a tailwind for revenue and less of a headwind for gross margin	• Monitoring volatility

Net impact from current tariffs/Fx: Revenue tailwind & EPS Neutral/Positive

Revenue Splits 2024



2024 Total Revenue: $634.4M

REPLIGEN



Upstream Systems and Consumables

Perfusion Technologies:
XCell® ATF Systems
KrosFlo® TFDF® Systems
KrosFlo® KPS TFF System

Consumables:
Spectrum® Hollow Fiber Filters
ProConnex® Flow Paths
Cell Culture Supplements

Harvest Systems and Consumables

KrosFlo® RS RPM TFF Systems
KrosFlo® TFDF® Systems
Spectrum® Hollow Fiber Filters
TangenX® Flat Sheet Cassettes
ProConnex® Flow Paths
SoloVPE® & FlowVPX® Systems

Downstream Systems and Consumables

KRM™ Chromatography Systems
OPUS® Pre-Packed Columns
AVIPure® Affinity Resins
Protein A Ligands
SoloVPE® & FlowVPX® Systems
ELISA® Kits

KrosFlo® RS RPM TFF Systems
Spectrum® Hollow Fiber Filters
TangenX® Flat Sheet Cassettes
ProConnex® Flow Paths
SoloVPE® & FlowVPX® Systems

Single-Use Consumables

ProConnex® Bags
ProConnex® MixOne
ProConnex® Assemblies
ProConnex® Secure Carrier

REPLIGEN

Reconciliation Tables

REPLIGEN

2024 Reconciliation – Earnings Per Share

Reconciliation of (Loss) Earnings Per Share (GAAP) to Adjusted Earnings Per Share (Non-GAAP)

	Three Months Ended December 31,		Year Ended December 31,	
	2024	2023	2024	2023
(LOSS) EARNINGS PER SHARE (GAAP) - DILUTED	(0.60)	$ (0.29)	(0.46)	$ 0.63
ADJUSTMENTS TO (LOSS) EARNINGS PER SHARE (GAAP) - DILUTED:				
Inventory step-up charges	-	0.02	-	$ 0.02
Acquisition and integration costs	0.04	0.02	0.13	$ 0.10
Restructuring activities and other related charges[3]	0.80	0.15	0.83	$ 0.57
Incremental costs attributed to CEO transition[4]	0.00	-	0.40	$ -
Contingent consideration	0.06	0.01	0.06	$ (0.54)
Intangible amortization	0.15	0.16	0.61	$ 0.56
Loss on extinguishment of debt	-	0.22	-	$ 0.22
Non-cash interest expense	0.07	0.01	0.25	$ 0.02
Amortization of debt issuance costs	0.01	0.12	0.03	$ 0.14
Foreign currency impact of certain intercompany loans [6]	0.09	(0.14)	0.10	$ (0.14)
Other[5]	0.03	-	0.04	$ -
Tax effect of non-GAAP charges	(0.21)	0.20	(0.41)	$ 0.07
ADJUSTED EARNINGS PER SHARE (NON-GAAP) - DILUTED[7]	$ 0.44	$ 0.48	$ 1.58	$ 1.65

REPLIGEN

Footnotes to EPS table on previous page

(3) In July 2023, the Board of Directors authorized the Company's management team to undertake restructuring activities to simplify and streamline our organization and strengthen the overall effectiveness of our operations. Since the initial streamlining and rebalancing efforts contemplated in July 2023, and with the introduction of new management in the second half of 2024, the Company continues to undertake further restructuring activities (collectively, the "Restructuring Plan") which has included consolidating a portion of our manufacturing operations between certain U.S. locations, writing-off abandoned equipment with the rationalization of excess production line capacity and discontinuing the sale of certain product SKUs. In addition, the Company continues to evaluate the net realizable value of finished goods and raw materials to meet rapidly changing demand during a challenging supply chain environment in the industry.

The Company recorded pre-tax costs of $46.9 million and $32.2 million in the years ended December 31, 2024 and 2023, respectively, related to the Restructuring Plan and other inventory-related charges. The Company believes the Restructuring Plan is now primarily complete as of December 31, 2024.

Severance and employee-related costs are primarily associated with headcount reductions. Costs incurred include cash severance and non-cash severance, including other termination benefits. Severance and other termination benefit packages are based on established benefit arrangements or local statutory requirements and we recognized the contractual component of these benefits when payment was probable and could be reasonably estimated.

Non-cash charges for the inventory write-off in 2023 included the impact of the Company discontinuing the sale of certain product SKUs, the impact of having proactively secured materials during the 2020-2022 pandemic period to meet accelerated demand during a challenging supply chain environment in the industry, and the impact of closing manufacturing facilities and production lines which include inventory that could not be repurposed. Where demand has reduced, finished goods and raw materials, the value of which exceeded the projected requirements to be used before reaching their expiration date, were written off.

The non-cash inventory write-off in 2024 includes the impact of the Company discontinuing the sale of certain product SKUs and is also the result of the further evaluation of inventory positions in unusually turbulent market supply conditions. This further evaluation took into consideration the market reset that continued into 2024 and resulted in new senior product management leadership updating product strategies. With these updated strategies, future demand and product mix projections were revised as a part of the Company's annual strategic planning and budget sessions in 2024. Where the value of finished goods and raw materials exceeded the projected requirements to be used before reaching their expiration date, or in a reasonable time horizon, they were written off.

In the fourth quarter of 2024, non-cash charges were recognized for the write-off of abandoned equipment in connection with unneeded capacity related to a specific product line that was also included in the 2024 inventory adjustment. The Company's manufacturing strategy and footprint were also reviewed as a part of our 2024 annual strategic planning and budget session. For this product line, capacity was expanded during the pandemic period, and current projections indicate it will not be needed in a usable time-period. The factory space will be reallocated for the production of other product lines.

Footnotes to EPS table (continued)

(4) Incremental stock compensation expense recorded during the three and twelve months ended December 31, 2024 of $16 and $22,362 respectively, attributable to the transition of the Company's Chief Executive Officer ("CEO") to Executive Chair of the Board announced by the Company on June 12, 2024. The incremental stock compensation expense was the result of the modification of the unvested equity awards held by the CEO immediately prior to the modification. This resulted in the revalue of his unvested awards and a change in his remaining requisite service period due to his change in duties upon transitioning to Executive Chair of the Board.

(5) Includes a one time events relating to a cybersecurity incident, net of insurance, and costs associated with the restatement of previously issued financial statements.

(6) During the three and twelve months ended December 31, 2024 we recorded foreign currency adjustments on certain intercompany loans of ($4,883) and ($5,509) respectively. The impact was recorded to the Other income (expenses), net line item within the Condensed Consolidated Statements of Operations.

(7) GAAP loss per share - diluted for the three and twelve months ended December 31, 2024, was determined excluding the effect of dilutive shares as the impact of such shares would have been antidilutive due to the net loss for the period, while the adjusted earnings per share - diluted for the same period was determined based upon diluted shares.

2025 Guidance Reconciliation – Earnings Per Share

Reconciliation of Earnings Per Share (GAAP) Guidance to Adjusted Earnings Per Share (Non-GAAP) Guidance

	Year Ending December 31, 2025	
	Low End	High End
GUIDANCE ON EARNINGS PER SHARE (GAAP) - DILUTED	$ 0.76	$ 0.85
ADJUSTMENTS TO GUIDANCE ON EARNINGS PER SHARE (GAAP) - DILUTED:		
Acquisition and integration costs	0.20	0.20
Restructuring activities and other related charges[1]	0.03	0.03
Anticipated pre-tax amortization of acquisition-related intangible assets	0.59	0.59
Non-cash interest expense	0.26	0.26
Amortization of debt issuance costs	0.03	0.03
Tax effect of non-GAAP charges	(0.24)	(0.24)
Other[2]	0.01	0.01
Guidance rounding adjustment	(0.01)	(0.01)
GUIDANCE ON ADJUSTED EARNINGS PER SHARE (NON-GAAP) - DILUTED	$ 1.63	$ 1.72

REPLIGEN

2014 Reconciliation – Earnings Per Share

Reconciliation of Earnings Per Share (GAAP) to Adjusted Earnings Per Share (Non-GAAP)

	Twelve months ended December 31, 2014
EARNINGS PER SHARE (GAAP) - DILUTED	$ 0.25
ADJUSTMENTS TO EARNINGS PER SHARE (GAAP) - DILUTED	
Royalty and other revenue	$ (0.09)
Acquisition and integration	$ 0.02
Contingent consideration	$ 0.06
ADJUSTMENTS TO EARNINGS PER SHARE (NON-GAAP) - DILUTED	$ 0.24

REPLIGEN

2019 Reconciliation – Earnings Per Share

Reconciliation of Earnings Per Share (GAAP) to Adjusted Earnings Per Share (Non-GAAP)

	Twelve months ended December 31, 2019
EARNINGS PER SHARE (GAAP) - DILUTED	$ 0.44
ADJUSTMENTS TO EARNINGS PER SHARE (GAAP) - DILUTED	
Acquisition and integration	$ 0.26
Inventory step-up charges	$ 0.03
Intangible amortization	$ 0.27
Loss on extinguishment of debt	$ 0.11
Non-cash interest expense	$ 0.15
Tax effect of intangible amortization and acquisition costs	$ (0.20)
ADJUSTMENTS TO EARNINGS PER SHARE (NON-GAAP) - DILUTED	$ 1.07

REPLIGEN

Questions?

Contact investors@repligen.com

REPLIGEN